Isozyme‐Specific Inhibition of GSK‐3 Reveals Distinct Cellular Responses in Huntington's Disease Fibroblasts
Journal of Neurochemistry · 2026-11 · 170 (11)
DOI: 10.1111/jnc.70588 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 09.11.2026. Verfasst von Yarine Lugassy und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Genetics and Computational Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel. Hauptthemen laut MEDLINE: Fibroblasts, Glycogen Synthase Kinase 3, Huntington Disease, Glycogen Synthase Kinase 3 beta. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Israel Science Foundation, Taube-Koret Global Collaboration in Neurodegenerative Diseases, The Smoler Proteomics Center, Technion, Haifa, Israel.
Abstract (Originalsprache)
Inhibition of glycogen synthase kinase‐3 (GSK‐3) has been implicated in alleviating Huntington's disease (HD)‐associated phenotypes. However, the mechanisms linking GSK‐3 to HD pathogenesis, and particularly the distinct roles of GSK‐3 isozymes in regulating HD‐associated cellular dysfunction, remain poorly understood. Here, we investigated the cellular responses of patient‐derived HD fibroblasts to selective inhibition of GSK‐3α or GSK‐3β using isozyme‐specific inhibitors, focusing on metabolic and bioenergetic pathways. Although inhibition of either isozyme suppressed mTORC1 signaling, selective GSK‐3β inhibition elicited broader cellular responses, including altered oxidative stress signaling, increased expression of proteins associated with mitochondrial fission, enhanced lysosomal activity, and mitophagy, together with lysosomal redistribution and increased α‐tubulin acetylation, suggesting improved microtubule‐dependent intracellular trafficking. Quantitative proteomic analysis of four independent patient‐derived HD fibroblasts corroborated these findings: GSK‐3β inhibition elicited a broad set of proteins involved in cytoskeletal organization, adhesion signaling, and metabolic adaptation, whereas GSK‐3α inhibition produced a more restricted and heterogeneous response. Collectively, these findings identify distinct cellular responses to selective GSK‐3 isozyme inhibition and reveal GSK‐3β as a predominant regulator of intracellular trafficking and mitochondrial and cytoskeletal dynamics in HD fibroblasts. Thus, inhibition of GSK‐3β may represent a potential therapeutic approach for modulating HD‐associated cellular dysfunction. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Genetics and Computational Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.
- Smoler Proteomics Center, Technion, Haifa, Israel.
ORCID-Profile: Tamar Ziv, Hagit Eldar-Finkelman
Förderung
- Israel Science Foundation
- Taube-Koret Global Collaboration in Neurodegenerative Diseases
- The Smoler Proteomics Center, Technion, Haifa, Israel
Zitieren
APA
Lugassy, Y., Berent, E., Jeries, S., Ziv, T., & Eldar-Finkelman, H. (2026). Isozyme‐Specific Inhibition of GSK‐3 Reveals Distinct Cellular Responses in Huntington's Disease Fibroblasts. Journal of Neurochemistry, 170(11). https://doi.org/10.1111/jnc.70588
Vancouver
Lugassy Y, Berent E, Jeries S, Ziv T, Eldar-Finkelman H. Isozyme‐Specific Inhibition of GSK‐3 Reveals Distinct Cellular Responses in Huntington's Disease Fibroblasts. Journal of Neurochemistry. 2026;170(11). doi:10.1111/jnc.70588
BibTeX
@article{Lugassy2026,
author = {Lugassy, Yarine and Berent, Eva and Jeries, Sandra and Ziv, Tamar and Eldar-Finkelman, Hagit},
title = {Isozyme‐Specific Inhibition of GSK‐3 Reveals Distinct Cellular Responses in Huntington's Disease Fibroblasts},
journal = {Journal of Neurochemistry},
year = {2026},
volume = {170},
number = {11},
doi = {10.1111/jnc.70588}
}
EUVIMED